ACRX


Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Announces Presentation Of Sublingual Sufentanil Data At The Society of American Gastrointestinal and Endoscopic Surgeons Meeting

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that a poster presentation will be made at the Annual Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) …

Canaccord Reiterates Hold on AcelRx Pharmaceuticals Inc After FDA Setback

Canaccord Genuity’s healthcare analyst John Newman weighed in today with his views on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), after the company reported that the FDA is requesting …

Canaccord Reiterates Hold Rating On Acelrx Pharmaceuticals Following Positive Feedback From The FDA

In a research report released Tuesday, Canaccord Genuity analyst John Newman maintained a Hold rating on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) with an $8.00 price target, …

Canaccord Remains Cautious On Acelrx Pharmaceuticals Ahead Of FDA Zalviso Feedback

In a research report issued today, Canaccord Genuity analyst John Newman maintained a Hold rating on Acelrx Pharmaceuticals (NASDAQ:ACRX) with an $8 price target, …

Roth Capital Remains Neutral On Acelrx Pharmaceuticals Following 3Q14 Update

Roth Capital analyst Ed Arce is out with his second note this week on Acelrx Pharmaceuticals (NASDAQ:ACRX) maintaining a Neutral rating with a $6 price target, following …

Roth Capital Remains Neutral On Acelrx As CEO Richard King Steps Down

Roth Capital analyst Ed Arce reaffirmed a Neutral rating on Acelrx Pharmaceuticals (NASDAQ:ACRX) with a $6 price target, as the company announced that CEO Richard …

Roth Capital Reiterates Neutral On Acelrx Pharmaceuticals, $6 PT

In a research report issued today, Roth Capital analyst Ed Arce reiterated a Neutral rating on Acelrx Pharmaceuticals (NASDAQ:ACRX) with a price target …

Unclear If AcelRx Can Address Optical Errors For Zalviso Without Clinical Work, Says Canaccord

In a report issued yesterday, Canaccord Genuity analyst John Newman assigned a Hold rating on shares of AcelRx Pharmaceuticals (ACRX) with a price target of $8, following ACRX’s Zalviso …

Roth Capital Affirms Buy On AcelRx Pharmaceuticals Despite FDA Rejection

In a research report issued today, Roth Capital analyst Ed Arce affirmed a Buy rating on AcelRx Pharmaceuticals Inc. (ACRX) and reduced his price target to $16 (from $22), following …

AcelRx: We See A Buying Opportunity One Week Before Zalviso PDUFA, Says Roth Capital

In a research report issued today, Roth Capital analyst Ed Arce affirmed a Buy rating on AcelRx Pharmaceuticals Inc. (ACRX) with a $22 price target, which represents 121% upside to the current share …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts